Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5BVD1
UPID:
TTMP_HUMAN
Alternative names:
-
Alternative UPACC:
Q5BVD1; B4DNV2; B4E0Z2; Q96AJ4; Q9H5Q1
Background:
The TPA-induced transmembrane protein plays a crucial role in the LIPH-mediated synthesis of 2-acyl lysophosphatidic acid (LPA), a key lipid mediator essential for various biological processes including hair formation and growth. This protein's involvement in LPA synthesis positions it as a significant player in cellular signaling and physiological regulation.
Therapeutic significance:
Linked to Hypotrichosis 15, a condition marked by reduced hair quantity and abnormal follicles, the TPA-induced transmembrane protein's genetic variants underscore its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for hair growth disorders.